Scarica l'app Stockscreener
3.32
1.53%
0.05
Precedente Chiudi:
$3.27
Aprire:
$3.3
Volume 24 ore:
55,875
Relative Volume:
1.13
Capitalizzazione di mercato:
$17.76M
Reddito:
-
Utile/perdita netta:
$-16.35M
Rapporto P/E:
-1.0885
EPS:
-3.05
Flusso di cassa netto:
$-11.88M
1 W Prestazione:
+4.73%
1M Prestazione:
+3.75%
6M Prestazione:
-29.21%
1 anno Prestazione:
-44.20%
Intervallo 1D:
$3.2911
$3.58
Intervallo di 1 settimana:
$3.10
$3.58
Portata 52W:
$2.6838
$6.1683
Lipocine Inc Stock (LPCN) Company Profile
Nome
Lipocine Inc
Settore
Industria
Telefono
801 994 7383
Indirizzo
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Confronta LPCN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.32 | 17.44M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-06-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Reiterato | H.C. Wainwright | Buy |
| 2018-01-11 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
| 2015-06-23 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Lipocine Inc Borsa (LPCN) Ultime notizie
What analysts say about Lipocine Inc. stockHigh-impact stock picks - PrintWeekIndia
Is Lipocine Inc. a good long term investmentFree Wealth Planning Blueprint - Autocar Professional
What drives Lipocine Inc. stock priceBreakthrough stock performance - jammulinksnews.com
Lipocine Inc. Stock Analysis and ForecastSpectacular growth rates - jammulinksnews.com
What makes Lipocine Inc. stock price move sharplyTrade With Low Risk Exposure - beatles.ru
How Lipocine Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser
Why Lipocine Inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
Lipocine stock maintains Buy rating at H.C. Wainwright on PPD treatment potential - Investing.com Australia
Lipocine stock maintains Buy rating at H.C. Wainwright as Phase 3 trial begins - Investing.com
First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial - Patient Care Online
LPCN Begins Pivotal Phase 3 Trial for Postpartum Depression Treatment | LPCN Stock News - GuruFocus
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression - Financial Times
Lipocine to Host R&D Event on July 9 - TipRanks
HC Wainwright Estimates Lipocine’s Q1 Earnings (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Given Buy Rating at HC Wainwright - Defense World
LPCN Stock Maintains 'Buy' Rating with $8.00 Price Target | LPCN Stock News - GuruFocus
Lipocine partner files for Canadian approval of oral TRT drug By Investing.com - Investing.com South Africa
Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine - Nasdaq
LPCN: Lipocine's TRT Submission in Canada Marks Key Milestone | - GuruFocus
Lipocine Announces Filing Of New Drug Submission For TLANDO In Canada - MarketScreener
Lipocine Inc Azioni (LPCN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):